Higher prevalence of metabolic syndrome and related factors in patients with first-episode psychosis and schizophrenia: a cross-sectional study in Turkey

References

• Skibinska M, Kapelski P, Rajewska-Rager A, et al. Correlation of metabolic parameters, neurotrophin-3, and neurotrophin-4 serum levels in women with schizophrenia and first-onset depression. Nord J Psychiatry. 2019;73(2):96–103.
   PubMed Web of Science ®Google Scholar
• Ko Y-K, Soh M-A, Kang S-H, et al. The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics. Clin Psychopharmacol Neurosci. 2013;11(2):80–88.
   PubMed Web of Science ®Google Scholar
• Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018;20(1):63–73.
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123–1131.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Vincenzi B, Andrea NV, et al. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015;2(5):452–464.
   PubMed Web of Science ®Google Scholar
• Hasnain M, Fredrickson SK, Vieweg WV, et al. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010;10(3):209–216.
   PubMed Web of Science ®Google Scholar
• De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83(1):87–93.
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Niskanen L, Lyytikäinen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64(5):575–579.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32.
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA. 2002;287(3):356–359.
   PubMed Web of Science ®Google Scholar
• Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–448.
   PubMed Web of Science ®Google Scholar
• Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl. 2004;47:S67–S71.
   PubMedGoogle Scholar
• Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 2015;12(5):267–277.
   PubMed Web of Science ®Google Scholar
• Kaffashian S, Dugravot A, Elbaz A, et al. Predicting cognitive decline: a dementia risk score vs. the Framingham vascular risk scores. Neurology. 2013;80(14):1300–1306.
   PubMed Web of Science ®Google Scholar
• Zhang C, Fang X, Yao P, et al. Metabolic adverse effects of olanzapine on cognitive dysfunction: a possible relationship between BDNF and TNF-alpha. Psychoneuroendocrinology. 2017;81:138–143.
   PubMed Web of Science ®Google Scholar
• MacKenzie NE, Kowalchuk C, Agarwal SM, et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry. 2018;9(622):1–12.
   PubMedGoogle Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• World Health Organizations. Physical status: the use and interpretation of anthropometry. Geneva (Switzerland): WHO; 1995. (Report of a WHO Expert Committee. Technical Report Series No. 854).
   Google Scholar
• Adult Treatment Panel III. Expert panel on detection and evaluation of treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA. 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Brewer HB, Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition . Circulation. 2004;109(3):433–438.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels (Belgium): International Diabetes Federation; 2005.
   Google Scholar
• Meyer JM. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial. J Clin Psychiatry. 2007;68:28–33.
   PubMed Web of Science ®Google Scholar
• Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017;47(6):1030–1040.
   PubMed Web of Science ®Google Scholar
• Said MA, Sulaiman AH, Habil MH, et al. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia. Singapore Med J. 2012;53(12):801–807.
   PubMed Web of Science ®Google Scholar
• Grover S, Aggarwal M, Dutt A, et al. Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiatry Res. 2012;200(2–3):1035–1037.
   PubMed Web of Science ®Google Scholar
• John AP, Koloth R, Dragovic M, et al. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust. 2009;190(4):176–179.
   PubMed Web of Science ®Google Scholar
• Aly El-Gabry DM, Abdel Aziz K, Okasha T, et al. Antipsychotic polypharmacy and its relation to metabolic syndrome in patients with schizophrenia: an Egyptian study. J Clin Psychopharmacol. 2018;38(1):27–33.
   PubMed Web of Science ®Google Scholar
• Heald A, Pendlebury J, Anderson S, et al. Lifestyle factors and the metabolic syndrome in Schizophrenia: a cross-sectional study. Ann Gen Psychiatry. 2017;16(1):12.
   PubMedGoogle Scholar
• Cerit C, Ozten E, Yildiz M. The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turkish J Psychiatry. 2008;19:124–132.
   Google Scholar
• Kurt E, Antinbas K, Alatas G, et al. Metabolic syndrome prevalence among schizophrenic patients treated in chronic inpatient clinics. Türkiye’de Psikiyatri. 2007;9:141–145.
   Google Scholar
• Yazici MK, Anil Yağcioğlu AE, Ertuğrul A, et al. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci. 2011;261(1):69–78.
   PubMed Web of Science ®Google Scholar
• Hägg S, Lindblom Y, Mjörndal T, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol. 2006;21:93–98.
   PubMed Web of Science ®Google Scholar
• Tirupati S, Chua L-E. Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas Psychiatry. 2007;15(6):470–473.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24:7–14.
   PubMedGoogle Scholar
• Altinbas K, Kurt E, Oral E. Endocrine side effects of second generation antipsychotics: is it rule or exception? Anatolian J Psychiatry. 2005;6:259–266.
   Google Scholar
• Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1–3):91–100.
   PubMed Web of Science ®Google Scholar
• Alptekin K, Erkoc S, Gogus AK, et al. Co-morbid substance abuse and smoking in Turkish patients with schizophrenia. 11. Bienial Winter Workshop on Schizophrenia. Schizophr Res. 2002;53:224.
   Web of Science ®Google Scholar
• Oyekcin DG. The frequency of metabolic syndrome in patients with schizophrenia and schizoaffective disorder. Anatolian J Psychiatry. 2009;10:26–33.
   Google Scholar
• Kaya MC, Virit O, Altındag A, et al. Prevalence of metabolic syndrome, characteristics of metabolic syndrome and relationship with the antipsychotics used in schizophrenia. Arch of Neuropsychiatry. 2009;46:13–18.
   Google Scholar
• Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull. 2013;39(2):306–318.
   PubMed Web of Science ®Google Scholar
• Ventriglio A, Gentile A, Stella E, et al. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci. 2015;9:297.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and metaanalysis. World Psychiatr. 2015;14(3):339–347.
   PubMed Web of Science ®Google Scholar
• Straker D, Correll CU, Kramer-Ginsberg E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications . Am J Psychiatry. 2005;162(6):1217–1221.
   PubMed Web of Science ®Google Scholar
• Bermudes RA, Keck PE, Jr, Welge JA. The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders. Psychosomatics. 2006;47(6):491–497.
   PubMed Web of Science ®Google Scholar
• Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25(2):83–88.
   PubMed Web of Science ®Google Scholar
• Campion J, Checinski K, Nurse J, et al. Smoking by people with mental illness and benefits of smoke-free mental health services. Adv Psychiatr. 2008;14(3):217–228.
   Google Scholar
• Baker AL, Lubman DI, Hides L. Smoking and schizophrenia: treatment approaches within primary care. Prim Psychiatry. 2010;17(1):49.
   Google Scholar
• Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007;90(1–3):162–173.
   PubMed Web of Science ®Google Scholar
• Marthoenis M, Aichberger MC, Puteh I, et al. Metabolic syndrome among psychiatric inpatients with schizophrenia in Indonesia. Asian J Psychiatr. 2015;15:10–14.
   PubMed Web of Science ®Google Scholar